The 2019 version of medical insurance negotiation ended, and a new round of competition of Chinese Biomedical enterprises began!

Dividends The 2019 version of medical insurance negotiation is settled, and a new round of competition of Chinese Biomedical enterprises is about to start! On November 28, the State Health Insurance Bureau officially released the 2019 medical insurance negotiation access list Among the 150 negotiated drugs, 70 of the 119 new drugs (52 western drugs and 18 Chinese patent drugs) were negotiated successfully, with an average price reduction of 60.7% 27 of the 31 renewed drugs were successfully negotiated (22 western medicine varieties and 5 Chinese patent medicine varieties), with an average price drop of 26.4% After this round of adjustment, there are 2709 drugs included in the catalogue of national basic medical insurance, industrial injury insurance and maternity insurance drugs in 2019 Compared with the 2017 version, 218 drugs are transferred in, 154 drugs are transferred out, and 64 drugs are increased net This negotiation is the largest one on drug catalog access since the establishment of the National Health Insurance Bureau From the perspective of the key disease areas involved, the drugs successfully negotiated in this negotiation involve more than 10 clinical treatment areas, including cancer, rare disease, hepatitis, diabetes, MDR-TB, rheumatism immunity, cardio cerebrovascular disease, digestion, etc through this negotiation, the guarantee ability of major diseases will be significantly improved, which will help more Chinese patients greatly improve the access and affordability of innovative drugs Most of the drugs successfully negotiated in this negotiation are newly marketed drugs with high clinical value in recent years, many of which are newly marketed in 2018 For example, among the new drugs, pyrrolidine maleate tablets and thiopefiglitazidine injection of Hengrui medicine were newly launched in 2018; Cinda bio's PD-1 inhibitor, cindilimab, was officially approved on December 27, 2018, and officially launched in February this year; Novartis' indadatro / glumonium bromide for the treatment of COPD was only launched in China on March 16, 2019 Among them, as the only PD-1 inhibitor negotiated successfully, the large price reduction of cindilimab also caused a lot of hot discussion and thinking As we all know, biopharmaceutical enterprises need to invest a lot of money in research and development and clinical stage As a new drug just on the market, it will be so low price Will it have a negative impact on enterprise itself and industry research and development innovation? During the 19th China biological products annual conference 2019 and cbiopc, Sina Pharma interviewed Mr Yuan Quanhong, President of CCB capital, on relevant topics of the pharmaceutical negotiation In response to the above issues, Mr Yuan Quanhong holds a positive view: "first of all, the pharmaceutical negotiation is applied by the enterprise itself, and the price is negotiated by both parties Since the enterprise is willing to accept, it means that the price has its rationality Another reason is to exchange price for quantity If the quantity is large, the cost of production and other aspects will be reduced accordingly " It is recalled that in March 2017, the original CFDA website published the decision on adjusting the matters related to the registration and management of imported drugs (Draft for comments) This 467 word draft for comments aroused thousands of waves In just over two years, China has continuously shortened the time difference between domestic and international listing of imported and innovative drugs In addition, the implementation of medical insurance negotiation access in recent years is a great encouragement for the innovation of international pharmaceutical enterprises, and a great touch and spur for local R & D enterprises Another feature of the successful drugs in this negotiation is the large number of imported drugs, reaching 49, accounting for more than half of the total Many multinational pharmaceutical enterprises also have outstanding performance For example, Xi'an Janssen, its Aike Tailong company and Novartis all have 7 outstanding products, which can be said to be the biggest winner of this round of health insurance negotiation Roche has 5 products selected, AstraZeneca and Geely have 4 products selected, Sanofi and Bayer have 3 products selected Among local pharmaceutical enterprises, Hengrui pharmaceutical is the most selected There are three enterprises.